Science News

from research organizations

This simple 3-amino acid trick boosts mRNA therapy 20-fold

A simple amino acid boost could turn today’s gene therapies into dramatically more powerful, near-perfect treatments.

Date:

April 20, 2026

Source:

Biohub

Summary:

A trio of common amino acids may hold the key to unlocking far more powerful gene therapies. Researchers found that adding them to lipid nanoparticles can boost mRNA delivery up to 20-fold and push CRISPR editing efficiency close to 90%. The trick isn’t changing the drug—but helping cells take it in more easily. In early tests, the approach dramatically improved survival and treatment outcomes, pointing to a simple but game-changing upgrade for future medicine.

Facebook

Twitter

FULL STORY

Artist's rendering of a lipid nanoparticle (blue spherical shape at left) supplemented by amino acids (depicted as chemical compounds) fusing with the cell membrane (red) to deliver therapeutic cargo (strands seen inside cell). Credit: Emma Hyde/Science Brush

Lipid nanoparticles, or LNPs, are best known for their role in delivering the COVID-19 mRNA vaccines given to billions of people. Now, scientists are expanding their use far beyond vaccines. Researchers are working to use these tiny carriers to deliver therapeutic mRNA into cells for cancer treatment, inflammatory diseases, and even CRISPR systems designed to fix harmful genetic mutations.

However, progress has been slowed by a persistent challenge. For LNPs to work inside the body, they must merge with cell membranes and release their cargo. While this process works efficiently in laboratory experiments, it is far less effective in real biological conditions.

Scientists Discover a Simple Amino Acid Solution

A research team at Biohub has identified an unexpectedly straightforward way to improve this process. In a study published in Science Translational Medicine, researchers led by Daniel Zongjie Wang, PhD, and Shana O. Kelley, Ph.D., showed that adding three common amino acids -- methionine, arginine, and serine -- alongside LNPs can dramatically enhance performance. This combination increased mRNA delivery by up to 20-fold and raised CRISPR gene editing efficiency from about 25 percent to nearly 90 percent after a single dose.

"Gene editing and mRNA-based therapies will play increasing roles in the medicine of the future, but they require LNPs to reach and enter cells," said Kelley, president of bioengineering at Biohub and head of Biohub, Chicago, where scientists are decoding the inflammatory processes that drive a wide range of diseases. "Any LNP formulation being developed today could potentially benefit from our approach."

The finding stems from the team's broader strategy of studying biology under conditions that better reflect the human body. "That's exactly what led us here," said Wang, who leads Biohub's Spatiotemporal Omics Group. "By asking why LNPs perform so differently in the physiological milieu of the body, we found a surprisingly simple answer that could make a wide range of mRNA and gene editing therapies substantially more effective."

A Metabolic Barrier Inside Cells

Until now, most efforts to improve LNP performance have focused on redesigning the nanoparticles themselves. Scientists have tested hundreds of new lipid combinations and used artificial intelligence to explore countless formulations. Despite these efforts, clinical results have remained underwhelming.

The Biohub researchers took a different approach. Instead of modifying the delivery system, they investigated whether the cells themselves were limiting uptake. They explored whether it might be possible to encourage cells to more readily absorb LNPs.

"The field has spent enormous effort engineering nanoparticles," said Wang. "We found, however, that the cell's own metabolic state is an equally important -- and addressable -- part of the equation."

Their work revealed that metabolism plays a key role. Standard lab-grown cells are exposed to nutrient-rich conditions that differ significantly from those inside the human body. When the team grew cells in a medium that more closely resembles human blood plasma, LNP uptake dropped sharply by 50 to 80 percent.

Further analysis showed that several amino acid-related metabolic pathways were less active under these more realistic conditions. This suggests that cells in the body operate with fewer available nutrients, which limits their ability to absorb nanoparticles.

A Simple Fix With Powerful Effects

To address this limitation, the researchers developed a targeted supplement containing methionine, arginine, and serine. When this mixture was given together with LNPs, the results were striking. Protein production from delivered mRNA increased between 5- and 20-fold across multiple cell types, both in laboratory experiments and in living animals.

The improvement held true across different delivery methods -- intramuscular, in